Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

53 results about "Immunoglobulin A" patented technology

Immunoglobulin A (IgA, also referred to as sIgA in its secretory form) is an antibody that plays a crucial role in the immune function of mucous membranes. The amount of IgA produced in association with mucosal membranes is greater than all other types of antibody combined. In absolute terms, between three and five grams are secreted into the intestinal lumen each day. This represents up to 15% of total immunoglobulins produced throughout the body.

Electrochemical luminescence immunosensor with low trigger potential and construction method and application thereof

PendingCN119086676AImplement low potential ECLSensitize ECL signalsMaterial electrochemical variablesDoped grapheneIntravenous gammaglobulin
The invention discloses an electrochemical luminescence immunosensor with low trigger potential and a construction method and application thereof, the sensor comprises a three-electrode system of an immune electrode, a reference electrode and a counter electrode, and when the electrochemical luminescence immunosensor is used, a detection solution comprises luminol and hydrogen peroxide; the immunoelectrode is an SNF modified electrode confined with metal palladium nanoparticles and nitrogen-doped graphene quantum dots, immunoglobulin A of immunospheres is covalently immobilized, then a primary antibody of a directionally immobilized tumor marker is constructed, and non-specific sites are closed, so that the immunoelectrode is obtained. The independent nano channel of the SNF film effectively avoids agglomeration of a confinement material, and the in-situ deposition mode is efficient and rapid; the good biocompatibility of the SNF provides a high-quality platform for the preparation of an immunosensing interface. The prepared immunosensor has the advantages of fast response speed, high ECL signal and good selective anti-interference capability, and has potential application prospects in tumor marker analysis and detection.
Owner:ZHEJIANG SCI-TECH UNIV

SNP molecular marker related to immune traits of yak and application of SNP molecular marker

The invention relates to the technical field of molecular biological detection, in particular to an SNP molecular marker related to immune traits of yaks and application of the SNP molecular marker. According to the invention, the SNP molecular marker related to the immune traits of yaks is obtained through screening and is located at the 55577127th position on the 22 # chromosome of a yak reference genome LUBosgruv3.0 version, and a mutant basic group is G or A. The content of immune globulin A, immune globulin G and immune globulin M of a yak individual can be obtained by utilizing the SNP molecular marker, a new SNP molecular marker resource is provided for non-diagnostic yak immune character marker-assisted selection, and a basis is provided for high-immunity yak breeding.
Owner:LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS

Molecular marker related to immune index of yak and application of molecular marker in breeding

The invention belongs to the technical field of molecular biological detection, and particularly relates to a molecular marker related to immune indexes of yaks and application of the molecular marker in breeding. The SNP molecular marker related to the immune traits of the yak is obtained through screening and is located at the 26593056th basic group of chromosome 3 of a yak reference genome LUBosgruv3.0 version, and the mutant basic group is G or A. The content of immune globulin A, immune globulin G and immune globulin M of a yak individual can be obtained by utilizing the SNP molecular marker, a new SNP molecular marker resource is provided for non-diagnostic yak immune character marker-assisted selection, and a basis is provided for high-immunity yak breeding.
Owner:LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS

Method for producing extracellular vesicles comprising fetus-derived primal immunoglobulin

ActiveUS12150962B2Skeletal/connective tissue cellsMammal material medical ingredientsNatural antibodyInnate immune system
A fetal stem cell-derived extracellular vesicle has immune tolerance properties. The extracellular vesicle containing a fetal stem cell-derived primal immunoglobulin contains various natural antibodies and complement proteins which can immediately respond to foreign infectious agents such as viruses, bacteria, pathogens, etc., and thus can effectively treat and prevent infectious diseases through an enhanced innate immune system. Methods are disclosed for preparing the fetal stem cell-derived extracellular vesicle.
Owner:STEMMEDICARE

Sparsentan for use in a method of treating IGA-mediated diseases

PCT designated stage expiredWO2024249509A1Organic active ingredientsUrinary disorderNephrosisDisease
Methods of preventing or treating immunoglobulin A-mediated diseases, such as immunoglobulin A nephropathy, by treatment with sparsentan, or a pharmaceutically acceptable salt thereof, are provided.
Owner:TRAVERE THERAPEUTICS INC

Application of bacillus subtilis QST713 in improving production performance and reproduction traits of Xiaoshan chicken

The invention discloses application of bacillus subtilis QST713 in improving the production performance and reproduction traits of Xiaoshan chickens. The production performance of the Xiaoshan chickens is improved by any one or more than two of the following steps: (1) reducing the feed-egg ratio of the Xiaoshan chickens; (2) the egg weight of Xiaoshan chicken is increased; (3) the egg protein height of Xiaoshan chicken is increased; (4) increasing any one or more of total protein, globulin and albumin in serum of the Xiaoshan chicken; (5) reducing any one or more of cholesterol, triglyceride, glutamic oxalacetic transaminase, glutamic-pyruvic transaminase and low-density lipoprotein in serum of the Xiaoshan chicken; and (6) increasing any one or more of immune globulin A, immune globulin G and immune globulin M in the serum of the Xiaoshan chicken. By adding the bacillus subtilis QST713 strain, the feed-egg ratio of the Xiaoshan chicken can be remarkably reduced, the egg quality and serum biochemical indexes of the Xiaoshan chicken can be effectively improved, the immune function is enhanced, and the ovarian gene expression of the Xiaoshan chicken is influenced.
Owner:ZHEJIANG ACADEMY OF AGRICULTURE SCIENCES

Method for preparing IgA dimer

The invention discloses a method for preparing an IgA (Immunoglobulin A) dimer. The invention provides a method for preparing an IgA dimer. The method comprises the following steps: (1) preparing a heavy chain expression plasmid and a light chain expression plasmid; the heavy chain expression plasmid is used for expressing heavy chain fusion protein; the heavy chain fusion protein sequentially comprises the following elements: a J chain, a self-shearing peptide, a secreting type signal peptide and an IgA antibody heavy chain, the light chain expression plasmid is used for expressing light chain fusion protein; the light chain fusion protein sequentially comprises the following elements: a secretory signal peptide and an IgA antibody light chain, and (2) co-transfecting mammalian cells with the heavy chain expression plasmid and the light chain expression plasmid, and culturing to obtain the IgA dimer. By adopting the method disclosed by the invention, a large amount of high-purity dimer IgA can be produced. The method is used for expression production of the dimer IgA, and has important theoretical guidance value and wide application prospect in research, clinical popularization, industrial production and the like of the dimer IgA antibody.
Owner:TSINGHUA UNIVERSITY

Lactic acid bacteria and immunostimulant

PendingCN120676874AMilk preparationBacteriaIMMUNE STIMULANTSDendritic cell
The present invention provides an immunologic stimulant which contains Lactobacillus helveticus, and wherein the Lactobacillus helveticus has three functions: the activation of dendritic cell-like cells, the induction of the production of immunoglobulin A (IgA), and the induction of the production of interleukin-12 (IL-12).
Owner:EZAKI GLICO CO LTD

A molecular marker g8087186 for rapid identification of immunity of Tibetan sheep and its application

The present invention belongs to the technical field of molecular biological detection, and in particular to a molecular marker g8087186 for rapid identification of Tibetan sheep immunity and its application. The present invention obtains a SNP molecular marker g8087186 related to Tibetan sheep immune traits by screening, which is located at the 8087186th base on chromosome 3 of the sheep reference genome group Oar_v4.0 version, and the mutant base is G or C. The SNP molecular marker can be used to obtain the content of immunoglobulin A, immunoglobulin G, and immunoglobulin M of Tibetan sheep individuals, and provides a new SNP molecular marker resource for marker-assisted selection of Tibetan sheep immune traits for non-diagnostic purposes. Provide a basis for breeding Tibetan sheep with high immunity.
Owner:LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS

Compositions and methods for treating infections of immune privileged organs comprising iga

PCT designated stageWO2026139149A1Nervous systemComplement system
The inventions relates to Immunoglobulin A (IgA) or a pharmaceutical composition comprising IgA for use in the treatment of an infectious disease of or in an immune privileged organ, such as the eye, fetus, placenta, central nervous system (CNS) and / or testicles caused by a bacterial, fungal, viral or parasitic infection, in particular caused by bacteria of the human microbiome. IgA-coated pathogens can be addressed by FCAR+ and / or CD11c+ innate immune cells, for example by phagocytosis, or by activation of the complement system. The use of IgA or a pharmaceutical composition comprising IgA in immune privileged sites is advantageous because in contrast to IgG, IgA-coated pathogens do not trigger activation of C1q, a protein used for the controlled pruning of synapses. This prevents neuronal damage in said immune privileged organ(s), while at the same time allowing an antibody-mediated immune response in said organs.
Owner:TECHNISCHE UNIVERSITAT DRESDEN

KCNJ6 gene as a molecular marker for immune traits in yaks and its application

The present invention belongs to the technical field of livestock molecular biology detection, and in particular, relates to the KCNJ6 gene as a molecular marker for yak immune traits and its application. The KCNJ6 gene is used as a molecular marker for yak immune traits, and the nucleotide sequence of the molecular marker is shown in SEQ ID NO: 1. The y at the 401st position of the sequence represents T or C, resulting in the T / C polymorphism of the yak KCNJ6 gene at this site. The present invention can determine the immunoglobulin A, immunoglobulin G, and immune content of individual yaks by detecting the base at the 163690745th nucleotide site on chromosome 1 of the yak. ​​The present invention provides a new SNP molecular marker resource for marker-assisted selection of yak immune traits for non-diagnostic purposes.
Owner:LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS

Lactic acid bacteria and immunostimulants

The present application provides an immunostimulant containing Lactobacillus helveticus, wherein the Lactobacillus helveticus has three functions: activation of dendritic cell-like cells, induction of immunoglobulin A (IgA) production, and induction of interleukin-12 (IL-12) production.
Owner:EZAKI GLICO CO LTD

A molecular marker-assisted breeding method for disease-resistant Tibetan sheep

The present invention belongs to the field of molecular biological detection technology, and in particular, relates to a molecular marker-assisted breeding method for Tibetan sheep with strong disease resistance. The present invention obtains a molecular marker for assisting the breeding of Tibetan sheep with strong disease resistance through screening, and the molecular marker is located at the 164719075th base on chromosome 3 of the sheep reference genome Oar_v4.0 version, and the mutant base is T or C. The molecular marker can be used to obtain the content of immunoglobulin A, immunoglobulin G, and immunoglobulin M of Tibetan sheep individuals, and provides a new molecular marker resource for marker-assisted selection of Tibetan sheep immune traits for non-diagnostic purposes. Provide a basis for breeding Tibetan sheep with high immunity.
Owner:LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS

Application of aesculetin in preparation of preparation for improving heat stress injury of poultry animals

ActiveCN120531726AOrganic active ingredientsAntinoxious agentsTotal protein serumPhysiology
The invention relates to application of aesculetin in preparation of a preparation for improving the health condition of poultry animals. The improved poultry animal abnormal indexes caused by heat stress comprise body weight, feed intake, daily gain, thymus index, spleen index, bursa of Fabricius index, thymus volume, spleen volume, bursa of Fabricius volume, total protein, serum albumin, interleukin-10, immune globulin A, immune globulin G, immune globulin M, triglyceride, total cholesterol and glutamic-pyruvic transaminase. The vaccine is prepared from the following raw materials: alkaline phosphatase, glutamic oxalacetic transaminase, urea nitrogen, lactic dehydrogenase, creatinine, heat shock protein 70, interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, interleukin-gamma, MyD88, TLR4, RELA, CD3 and CD19.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Immunological assay method, immunological assay reagent, immunological assay sample pretreatment liquid, immunological assay kit, and non-specific reaction inhibitor

An immunological assay method for measuring a target substance in a sample, wherein at least one antigen-antibody reaction is performed in the presence of an enzyme that specifically decomposes immunoglobulin A (IgA).
Owner:SEKISUI MEDICAL CO LTD

Iga for treatment and prevention of dry eyes

The present disclosure refers to Immunoglobulin A (IgA) for use in a method for treating or preventing dry eyes in a patient wherein said Immunoglobulin A (IgA) is obtained from plasma, blood plasma or plasma fractions, and wherein said Immunoglobulin A (IgA) is administered to said patient in an effective dosage. In particular, the disclosure pertains to the use in a treatment or prevention of dry eye disease and the respective complications like infections. Further, the disclosure refers to IgA obtained from plasma, blood plasma or plasma fractions and a pharmaceutical composition comprising such IgA.
Owner:PREVIPHARMA CONSULTING GMBH

Monoclonal antibody of immunoglobulin A and application thereof

The invention provides a monoclonal antibody of immunoglobulin A. The monoclonal antibody is a monoclonal antibody of specific immunoglobulin A secreted by a mouse anti-human immunoglobulin A monoclonal antibody hybridoma cell line 5F5A4F3 strain, can be used for quantitatively detecting the concentration of RBD-IgA generated by stimulation of a specific antigen, and also can be used for quantitatively detecting the concentration of the immunoglobulin A. The immunoglobulin A monoclonal antibody can be used for detecting the immunoglobulin A monoclonal antibody, can also be used for quantitatively detecting the concentration of total IgA generated by mucosal immunity, and is good in linearity, high in sensitivity, strong in specificity, suitable for evaluating the immune effect of vaccines, and also suitable for screening and monitoring the IgA antibody level in large-scale people.
Owner:BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO LTD +1

SNP Molecular Markers Related to Immune Traits of Yaks and Their Applications

The present invention relates to the field of molecular biology detection technologies, and particularly to SNP molecular markers related to the immune traits of yaks and their applications. The present invention screens out SNP molecular markers related to the immune traits of yaks, which are located at position 55577127 on chromosome 22 of the yak reference genome LU_Bosgru_v3.0 version, and the mutated base is G or A. The present invention can obtain the contents of immunoglobulin A, immunoglobulin G, and immunoglobulin M of yak individuals by using this SNP molecular marker, providing a new SNP molecular marker resource for marker-assisted selection of yak immune traits for non-diagnostic purposes and providing a basis for breeding yaks with high immunity.
Owner:LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS

A recombinant fusion protease capable of clearing immunoglobulin A in vivo, a preparation method thereof, and application thereof in treating IgA nephropathy

The present invention provides a recombinant fusion protein based on AK183 protease and its application in treating IgA nephropathy and other related diseases mediated by IgA complex deposition, wherein the recombinant fusion protein structure comprises a human commensal bacteria protease AK183 active region and a human immunoglobulin fragment; the human immunoglobulin fragment is located at the N-terminus of the protease AK183 active region. The present invention also provides a method for preparing the recombinant fusion protein. The recombinant fusion protein of the present invention has the comprehensive advantages of prolonged plasma half-life, effective clearance of circulating and renal IgA complexes, and greatly reducing the immunogenic side effects of the protease on the human body, by recombinantly fusing the natural AK183 protease with the human immunoglobulin fragment, and is suitable for specific treatment of IgA nephropathy and other related diseases mediated by IgA complex deposition.
Owner:PEKING UNIVERSITY FIRST HOSPITAL (PEKING UNIVERSITY FIRST CLINICAL MEDICAL COLLEGE) +1

BIFUNCTIONAL DEGRADERS OF IgG4 IMMUNOGLOBULINS

PCT designated stageWO2025158412A1Pharmaceutical non-active ingredientsImmunological disordersImmunoglobulin AAsialoglycoprotein
A composition of matter including an IgG4-binding moiety, a cellular receptor-binding moiety which binds to hepatocytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells in a patient or subject, and optionally, a linker moiety connecting the IgG4-binding moiety and the cellular receptor-binding moiety, wherein the composition of matter is useful for removing IgG4 from a subject or patient.
Owner:BIOHAVEN THERAPEUTICS LTD

Bifunctional degraders of galactose-deficient immunoglobulins

A composition of matter including a deglycosylated IgA-binding moiety, a cellular receptor-binding moiety that binds to hepatocytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells in a patient or subject, and optionally, a linker moiety connecting deglycosylated IgA-binding moiety and the cellular receptor-binding moiety, wherein the composition of matter is useful for removing galactose-deficient IgA1 in a patient or subject.
Owner:BIOHAVEN THERAPEUTICS LTD

Molecular marker associated with immune parameters in yaks and use thereof in breeding

A molecular marker associated with immune parameters in yaks and use thereof in breeding are provided. A single nucleotide polymorphism (SNP) molecular marker associated with immune traits in yaks is identified through screening. The SNP molecular marker is located at position 26593056 on chromosome 3 of the yak reference genome version LU_Bosgru_v3.0, and a nucleotide at the position is G or A. The SNP molecular marker is utilized to quantify levels of immunoglobulin A, immunoglobulin G, and immunoglobulin M in a yak individual, providing a novel SNP molecular marker resource for non-diagnostic, marker-assisted selection of immune traits in yaks, thereby providing a basis for breeding yaks with enhanced immune competence.
Owner:SERES ACADEMIAE AGRICULTURAE SCIENTIARUM LANZHOU INSTITUTUM ANIMAL PHARMACEUTICAL & VETERINARII

A composite preparation for fasting-induced physiological remodeling in laying hens and its application

The present invention discloses a composite formulation for fasting-induced physiological remodeling in laying hens and its application, belonging to the technical field of fasting-induced physiological remodeling. The composite formulation and method provided by the present invention can significantly increase the ileal villus height, the expression levels of intestinal barrier-related genes and intestinal proliferation-related genes of laying hens, significantly reduce the expression levels of intestinal pro-inflammatory-related genes, alleviate intestinal stress damage and inflammation, and thus significantly improve the intestinal health of laying hens; can significantly increase the expression levels of immunoglobulin A, immunoglobulin G, and immunoglobulin M, and thus improve the immune performance of laying hens; with the improvement of intestinal health and immunity, fasting-induced physiological remodeling of laying hens is successfully achieved: the weight and egg production recovery ability of laying hens after fasting, and the yolk color depth on the 30th day after fasting are significantly better than those of the control group, providing technical support for the extended breeding of laying hens, saving costs and increasing efficiency.
Owner:HENAN AGRICULTURAL UNIVERSITY

Treatment of al amyloidosis by combination of monoclonal antibody against immunoglobulin light chain and monoclonal antibody against CD38 cell membrane molecule on antibody-producing and other immune cells

To provide a treatment of AL amyloidosis by combination of a monoclonal antibody to an immunoglobulin light chain and a monoclonal antibody to a CD38 cell membrane molecule on antibody-producing cells or other immune cells.SOLUTION: Disclosed is a treatment of AL amyloidosis by combination of a monoclonal antibody against an immunoglobulin a light chain and aggregates thereof and a monoclonal antibody against a CD38 cell membrane molecule on antibody-producing or other immune cells. Typically, the effective dosage of these antibodies is effective to achieve an improvement in both hematologic and cardiac or other organ function. The dosage may be effective to achieve an improvement in both hematologic and organ function, for example, cardiac function.SELECTED DRAWING: None
Owner:PROTHENA BIOSCI LTD +1

Bifunctional degraders of galactose-deficient immunoglobulins

A composition of matter including a deglycosylated IgA-binding moiety, a cellular receptor-binding moiety that binds to hepatocytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells in a patient or subject, and optionally, a linker moiety connecting deglycosylated IgA-binding moiety and the cellular receptor-binding moiety, wherein the composition of matter is useful for removing galactose-deficient IgA1 in a patient or subject.
Owner:BIOHAVEN THERAPEUTICS LTD

Antigen-specific degraders of immunoglobulin a and their uses

Provided is a method of removal a pathogenic species from a system of a patient having Immunoglobulin A ("IgA") nephropathy by administering to the patient a degrader of galactose-deficient Immunoglobulin A ("Gd-IgA"), wherein the pathogenic species is a monomeric Gd-IgA, a dimeric Gd-IgA complex, a trimeric Gd-IgA complex, a tetrameric Gd-IgA complex, or a combination thereof.
Owner:BIOHAVEN THERAPEUTICS LTD

Method for removing IgA and IgM in human immunoglobulin for intravenous injection

The invention provides a method for removing IgA (Immunoglobulin A) and IgM (Immunoglobulin M) in human immunoglobulin for intravenous injection. The method comprises the following steps: S1) dissolving plasma component II + III precipitates to obtain a dissolved solution; s2) precipitating and centrifuging the dissolved solution by adopting n-caprylic acid or sodium caprylate to obtain supernate; s3) performing anion exchange column chromatography on the supernate to obtain first flow-through liquid and first washing liquid; s4) mixing the first flow-through liquid with the first washing liquid to obtain a column chromatography collection liquid; s5) performing strong anion membrane chromatography on the column chromatography collection liquid to obtain second flow-through liquid and second washing liquid; s6) mixing the second flow-through liquid and the second washing liquid to obtain a membrane chromatography collection liquid, and S7) sequentially performing first concentration, dialysis, first sterilization, incubation, ultrafiltration and second sterilization on the membrane chromatography collection liquid to obtain the human immunoglobulin for intravenous injection without IgA and IgM. According to the method disclosed by the invention, the IgA and IgM removal efficiency is remarkably improved through a multi-stage purification process.
Owner:SHANGHAI XINXING MEDICINE

METHODS FOR TREATING OR PREVENTING RESPIRATORY DISEASES IN CATTLE USING POLYMERS AND POLYPLEXES FOR mRNA DELIVERY AND mRNA THERAPY

A method of preventing or treating or controlling a respiratory disease in a bovine by delivering to a lung or trachea of the bovine a composition including a polyplex having one or more mRNA encoded with a molecule selected from lycosylphosphatidylinositol (GPI) complex, antibody immunoglobulin G (IgG), antibody immunoglobulin A (IgA), antibody immunoglobulin M (IgM), antimicrobial peptide Bactenecin 5 (Bac5), antimicrobial peptide Bactenecin 7 (Bac7), bovine myeloid antimicrobial peptide (BMAP-28), lipoxin inducing enzymes, resolvin inducing enzymes, cytokines, CRISPR associated protein 13 (Cas13) enzymes, nanoluciferase (NLuc) proteins, and gene activator, catalytically dead CRISPR-associated protein 9 fused to an activator selected from the group consisting of VP64-p65-Rta transactivation domain (dCas9-VPR), VP64, and VP64-p65-HSF1 on the N terminus and SS18 on the C-terminus, and a polymer prepared by polymerizing a diacrylate monomer; one or more linker monomers; and one or more branching monomers; and end-capping the polymer.
Owner:MISSISSIPPI STATE UNIVERSITY +1

A molecular marker related to immune indicators of Tibetan sheep and its application in breeding

The present invention belongs to the field of molecular biological detection technology, and more particularly relates to a molecular marker associated with immune indicators in Tibetan sheep and its application in breeding. The present invention screens and identifies a single-nucleotide polymorphism (SNP) molecular marker associated with immune traits in Tibetan sheep. The SNP marker is located at base 12,065,580 on chromosome 1 of the sheep reference genome Oar_v4.0, with the mutated base being either C or T. This SNP molecular marker can be used to determine the levels of immunoglobulin A, immunoglobulin G, and immunoglobulin M in individual Tibetan sheep, providing a new SNP molecular marker resource for marker-assisted selection of immune traits in Tibetan sheep for non-diagnostic purposes. This provides a basis for breeding Tibetan sheep with high immunity.
Owner:LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS